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Abstract
Body fat distribution is a heritable trait and a well-established predictor of adverse metabolic 
outcomes, independent of overall adiposity. To increase our understanding of the genetic basis of 
body fat distribution and its molecular links to cardiometabolic traits, we conducted genome-wide 
association meta-analyses of waist and hip circumference-related traits in up to 224,459 
individuals. We identified 49 loci (33 new) associated with waist-to-hip ratio adjusted for body 
mass index (WHRadjBMI) and an additional 19 loci newly associated with related waist and hip 
circumference measures (P<5×10−8). Twenty of the 49 WHRadjBMI loci showed significant 
sexual dimorphism, 19 of which displayed a stronger effect in women. The identified loci were 
enriched for genes expressed in adipose tissue and for putative regulatory elements in adipocytes. 
Pathway analyses implicated adipogenesis, angiogenesis, transcriptional regulation, and insulin 
resistance as processes affecting fat distribution, providing insight into potential 
pathophysiological mechanisms.
Depot-specific accumulation of fat, particularly in the central abdomen, confers an elevated 
risk of metabolic and cardiovascular diseases and mortality1. An easily accessible measure 
of body fat distribution is waist-to-hip ratio (WHR), a comparison of waist and hip 
circumferences. A larger WHR indicates more intra-abdominal fat deposition and is 
associated with higher risk for type 2 diabetes (T2D) and cardiovascular disease2,3. 
Conversely, a smaller WHR indicates greater gluteal fat accumulation and is associated with 
lower risk for T2D, hypertension, dyslipidemia, and mortality4-6. Our previous genome-
wide association study (GWAS) meta-analyses have identified loci for WHR after adjusting 
for body mass index (WHRadjBMI)7,8. These loci are enriched for association with other 
metabolic traits7,8 and show that different fat distribution patterns can have distinct genetic 
components9,10.
To further elucidate the genetic architecture of fat distribution and to increase our 
understanding of molecular connections with cardiometabolic traits, we performed a meta-
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analysis of WHRadjBMI associations in 142,762 individuals with GWAS data and 81,697 
individuals genotyped with the Metabochip11, all from the Genetic Investigation of 
ANthropometric Traits (GIANT) Consortium. Given the marked sexual dimorphism 
previously observed among established WHRadjBMI loci7,8, we performed analyses in men 
and women separately, the results of which were subsequently combined. To more fully 
characterize the genetic determinants of specific aspects of body fat distribution, we 
performed secondary GWAS meta-analyses for five additional traits: unadjusted WHR, 
BMI-adjusted and unadjusted waist (WCadjBMI and WC) and hip circumferences 
(HIPadjBMI and HIP). We evaluated the associated loci to understand their contributions to 
variation in fat distribution and adipose tissue biology, and their molecular links to 
cardiometabolic traits.
RESULTS
New loci associated with WHRadjBMI
We performed meta-analyses of GWAS of WHRadjBMI in up to 142,762 individuals of 
European ancestry from 57 new or previously described GWAS7, and separately in up to an 
additional 67,326 European ancestry individuals from 44 Metabochip studies (Extended 
Data Fig. 1; Supplementary Tables 1-3). The combination of these two meta-analyses 
included up to 2,542,447 autosomal SNPs in up to 210,088 European ancestry individuals. 
We defined new loci based on genome-wide significant association (P<5 × 10−8 after 
genomic control correction at both the study-specific and meta-analytic levels) and distance 
(>500 kb) from previously established loci7,8.
We identified 49 loci for WHRadjBMI, 33 of which were new and 16 previously 
described7,8. Of these, a European ancestry sex-combined analysis identified 39 loci, 24 of 
which were new (Table 1, Supplementary Table 4, and Supplementary Figs. 1-3)7,8. 
European ancestry sex-specific analyses identified nine additional loci, eight of which were 
new and significant in women but not in men (all Pmen>0.05; Table 1, Supplementary Fig. 
4). The addition of 14,371 individuals of non-European ancestry genotyped on Metabochip 
identified one additional locus in women (rs1534696, near SNX10, Pwomen=2.1×10−8, 
Pmen=0.26, Table 1, Supplementary Tables 1-3), with no evidence of heterogeneity across 
ancestries (Phet=0.86, Supplementary Note).
Genetic architecture of WHRadjBMI
To evaluate sexual dimorphism, we compared sex-specific effect size estimates of the 49 
WHRadjBMI lead SNPs. The effect estimates were significantly different 
(Pdifference<0.05/49=0.001) at 20 SNPs, 19 of which showed larger effects in women (Table 
1, Extended Data Fig. 2a), similar to previous findings7,8. The only SNP that showed a 
larger effect in men mapped near GDF5 (rs224333, βmen=0.036 and P=9.0×10−12, 
βwomen=0.009 and P=0.074, Pdifference= 6.4 × 10−5), a locus previously associated with 
height (rs6060369, r2=0.96 and rs143384, r2=0.96, 1000 Genomes Project CEU), though 
without significant differences between sexes12,13. Consistent with the larger number of loci 
identified in women, variance component analyses demonstrated a significantly larger 
heritability (h2) of WHRadjBMI in women than men in the Framingham Heart 
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(h2women=0.46, h2men=0.19, Pdifference=0.0037) and TwinGene studies (h2women=0.56, 
h2men=0.32, Pdifference=0.001, Supplementary Table 5, Extended Data Fig. 2b).
To identify multiple association signals within observed loci, we performed approximate 
conditional analyses of the sex-combined and sex-specific summary statistics using GCTA14 
(Supplementary Note). Multiple signals (P<5×10−8) were identified at nine loci (Extended 
Data Table 1). Fitting SNPs jointly identified different lead SNPs in the sex-specific and 
sex-combined analyses. For example, the MAP3K1-ANKRD55 locus showed near-
independent (linkage disequilibrium (LD) r2<0.06) SNPs 54 kb apart that were significant 
only in women (rs3936510) or only in men (rs459193, Extended Data Table 1, 
Supplementary Table 4). Other signals are more complex. The TBX15-WARS2 locus showed 
different but correlated lead SNPs in men and women near WARS2 (r2=0.43), an 
independent signal near TBX15, and a distant independent signal near SPAG17 (Fig. 1). At 
the HOXC gene cluster, conditional analyses identified independent (r2<0.01) SNPs ~80 kb 
apart near HOXC12-HOXC13-HOTAIR and near HOXC4-HOXC6 (Fig. 1). These results 
suggest that association signals mapping to the same locus might act on different underlying 
genes and may not be relevant to the same sex.
We assessed the aggregate effects of the primary association signals at the 49 WHRadjBMI 
loci by calculating sex-combined and sex-specific risk based on genotypes of the lead SNPs. 
In a linear regression model, the risk scores were associated with WHRadjBMI, with a 
stronger effect in women than in men (overall effect per allele β=0.001, P=6.7×10−4, women 
β=0.002, P=1.0×10−11, men β=7.0×10−4, P=0.02, Extended Data Fig. 3, Supplementary 
Note). The 49 SNPs explained 1.4% of the variance in WHRadjBMI overall, and more in 
women (2.4%) than in men (0.8%) (Supplementary Table 6). Compared to the 16 previously 
reported loci7,8, the new loci almost doubled the explained variance in women and tripled 
that in men. We further estimated that the sex-combined variance explained by all HapMap 
SNPs15 (h2G) is 12.1% (SE=2.9%).
At 17 loci with high-density coverage on the Metabochip11, we used association summary 
statistics to define credible sets of SNPs with a high probability of containing a likely 
functional variant. The 99% credible sets at seven loci spanned <20 kb, and at HOXC13 
included only a single noncoding SNP (Supplementary Table 7, Supplementary Fig. 5). 
Imputation up to higher density reference panels will provide greater coverage and may have 
more potential to localize functional variants.
WHRadjBMI variants and other traits
Given the epidemiological correlations between central obesity and other anthropometric 
and cardiometabolic measures and diseases, we evaluated lead WHRadjBMI variants in 
association data from GWAS consortia for 22 traits. Seventeen of the 49 variants were 
associated (P<5×10−8) with at least one of the traits: high-density lipoprotein cholesterol 
(HDL-C; n=7 SNPs), triglycerides (TG; n=5), low-density lipoprotein cholesterol (LDL-C; 
n=2), adiponectin adjusted for BMI (n=3), fasting insulin adjusted for BMI (n=2), T2D 
(n=1), and height (n=7) (Supplementary Tables 8-9). WHRadjBMI SNPs also showed 
enrichment for directional consistency among nominally significant (P<0.05) associations 
with these traits and also with fasting and 2-hour glucose, diastolic and systolic blood 
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pressure (DBP, SBP), BMI and coronary artery disease (CAD) (Pbinomial<0.05/23=0.0022, 
Extended Data Table 2); these results were generally supported by meta-regression analysis 
of the regression coefficient-estimates (Supplementary Table 10). Furthermore, our 
WHRadjBMI loci overlap with associations reported in the NHGRI GWAS Catalog (Table 
2, Supplementary Table 11)16, the strongest of which is the locus near LEKR1, which is 
associated (P=2.0×10−35) with birthweight17. Unsupervised hierarchical clustering of the 
corresponding matrix of association Z-scores showed three major clusters characterized by 
patterns of anthropometric and metabolic traits (Extended Data Fig. 4). These data extend 
knowledge about genetic links between WHRadjBMI and insulin resistance-related traits; 
whether this reflects underlying causal relations between WHRadjBMI and these traits, or 
pleiotropic loci, cannot be inferred from our data.
Potential functional WHRadjBMI variants
We next examined variants in LD with the WHRadjBMI lead SNPs (r2>0.7) for predicted 
effects on protein sequence, copy number, and cis-regulatory effects on expression (Table 2, 
Supplementary Tables 12-15, Supplementary Note). At 11 of the new loci, lead 
WHRadjBMI SNPs were in LD with cis-expression quantitative trait loci (eQTLs) for 
transcripts in subcutaneous adipose tissue, omental adipose tissue, liver, or blood cell types 
(Table 2, Supplementary Table 15). No additional sex-specific eQTLs were identified, 
perhaps reflecting limited power (Supplementary Table 16).
At the 11 WHRadjBMI loci harboring eQTLs, we compared the location of the candidate 
variants to regions of open chromatin (DNase I hypersensitivity and formaldehyde-assisted 
isolation of regulatory elements [FAIRE]) and histone modification enrichment (H3K4me1, 
H3K4me2, H3K4me3, H3K27ac, and H3K9ac) in adipose, liver, skeletal muscle, bone, 
brain, blood, and pancreatic islet tissues or cell lines (Supplementary Table 17). At seven of 
these 11 loci, at least one variant was located in a putative regulatory element in two or more 
datasets from the same tissue as the eQTL, suggesting that these elements may influence 
transcriptional activity (Supplementary Table 18). For example, at LEKR1, five variants in 
LD with the WHRadjBMI lead SNP are located in a 1.1 kb region with evidence of enhancer 
activity (H3K4me1 and H3K27ac) in adipose tissue (Extended Data Fig. 5a).
We also examined whether any variants overlapped with open chromatin or histone 
modifications from only one of the tested tissues, possibly reflecting tissue-specific 
regulatory elements (Supplementary Table 18). For example, five variants in a 2.2 kb region, 
located 77 kb upstream from a CALCRL transcription start site, overlapped with peaks in at 
least five datasets in endothelial cells (Extended Data Fig. 5b), suggesting that one or more 
of these variants may influence transcriptional activity. CALCRL, which is expressed in 
endothelial cells, is required for lipid absorption in the small intestine, and influences body 
weight in mice18. Other variants located in tissue-specific regulatory elements were detected 
at NMU for endothelial cells, at KLF13 and MEIS1 for liver, and at GORAB and MSC for 
bone (Supplementary Table 18).
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Biological mechanisms
To identify potential functional connections between genes mapping to the 49 WHRadjBMI 
loci, we used three approaches (Supplementary Note). A survey of literature using GRAIL19 
identified 15 genes with nominal significance (P<0.05) for potential functional connectivity 
(Table 2, Supplementary Table 19). The predefined gene set relationships across loci 
identified using MAGENTA20 highlighted signaling pathways involving vascular 
endothelial growth factor (VEGF), phosphatase and tensin (PTEN) homolog, the insulin 
receptor, and peroxisome proliferator-activated receptors (Supplementary Table 20). VEGF 
signaling plays a central, complex role in angiogenesis, insulin resistance, and obesity21, and 
PTEN signaling promotes insulin resistance22. Analyses using DEPICT23 facilitated 
prioritization of genes at associated loci, analyses of tissue specificity, and enrichment of 
reconstituted gene sets through integration of association results with expression data, 
protein-protein interactions, phenotypic data from gene knockout studies in mice, and 
predefined gene sets. DEPICT identified at least one prioritized gene (false discovery rate 
(FDR)<5%) at nine loci (Table 2, Supplementary Table 21) and identified 234 reconstituted 
gene sets (161 after pruning of overlapping gene sets) enriched for genes at WHRadjBMI 
loci. Among these we highlight biologically plausible gene sets suggesting roles in body fat 
regulation (including adiponectin signaling, insulin sensitivity, and regulation of glucose 
levels), skeletal growth, transcriptional regulation, and development (Fig. 2, Supplementary 
Table 22). We also note gene sets that are specific for abundance or development of 
metabolically active tissues including adipose, heart, liver, and muscle. Specific genes at the 
loci were significantly enriched (FDR<5%) for expression in adipocyte-related tissues, 
including abdominal subcutaneous fat (Fig. 2, Supplementary Table 23). Together, these 
analyses identified processes related to insulin and adipose biology and highlight 
mesenchymal tissues, especially adipose tissue, as important to WHRadjBMI.
We also tested variants at the 49 WHRadjBMI loci for overlap with elements from 60 
selected regulatory datasets from the ENCODE24 and Epigenomic RoadMap25 data and 
found evidence of enrichment in 12 datasets (P<0.05/60=8.3×10−4, Extended Data Table 3). 
The strongest enrichments were detected for datasets typically attributed to enhancer activity 
(H3K4me1 and H3K27ac) in adipose, muscle, endothelial cells, and bone, suggesting that 
variants may regulate transcription in these tissues. These analyses point to mechanisms 
linking WHRadjBMI loci to regulation of gene expression in tissues highly relevant for 
adipocyte metabolism and insulin resistance.
We also reviewed functions of candidate genes located near new and previously established 
WHRadjBMI loci7,8, identifying genes involved in adipogenesis, angiogenesis, and 
transcriptional regulation (Table 2, literature review in the Supplementary Note). 
Adipogenesis candidate genes include CEBPA, PPARG, BMP2, HOXC/miR196, SPRY1, 
TBX15, and PEMT. Of these, CEBPA and PPARG are essential for white adipose tissue 
differentiation26, BMP2 induces differentiation of mesenchymal stem cells toward 
adipogenesis or osteogenesis27, and HOXC8 is a repressor of brown adipogenesis in mice 
that is regulated by miR-196a28, also located within the HOXC region (Fig. 1). Angiogenesis 
genes may influence expansion and loss of adipose tissue29; they include VEGFA, VEGFB, 
RSPO3, STAB1, WARS2, PLXND1, MEIS1, FGF2, SMAD6, and CALCRL. VEGFB is 
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involved in endothelial targeting of lipids to peripheral tissues30, and PLXND1 limits blood 
vessel branching, antagonizes VEGF, and affects adipose inflammation31,32. Transcriptional 
regulators at WHRadjBMI loci include CEBPA, PPARG, MSC, SMAD6, HOXA, HOXC, 
ZBTB7B, JUND, KLF13, MEIS1, RFX7, NKX2-6, and HMGA1. Other candidate genes 
include NMU, FGFR4, and HMGA1, for which mice deficient for the corresponding genes 
exhibit obesity, glucose intolerance, and/or insulin resistance33-35.
Five additional central obesity traits
To determine whether the WHRadjBMI variants exert their effects primarily through WC or 
HIP and to identify loci that are not reported for WHRadjBMI, BMI, or height36,37, we 
performed association analyses for five additional traits: WCadjBMI, HIPadjBMI, WHR, 
WC, and HIP. Based on phenotypic data alone, WC and HIP are highly correlated with BMI 
(r=0.59-0.92), and WHR is highly correlated with WHRadjBMI (r=0.82-0.95), while 
WCadjBMI and HIPadjBMI are moderately correlated with height (r=0.24-0.63, 
Supplementary Table 24). In contrast to WHRadjBMI, which has almost no genetic 
correlation (see Methods) with height (rG<0.04, Extended Data Fig. 2c), WCadjBMI 
(rG=0.42) and HIPadjBMI (rG=0.82) have moderate genetic correlations with height. These 
data suggest that some, but not all, WCadjBMI and HIPadjBMI loci would be associated 
with height.
Across all meta-analyses, we identified an additional 19 loci associated with one of the five 
traits (P<5×10−8), nine of which showed significantly larger effects 
(Pdifference<0.05/19=0.003) in one sex than in the other (Table 3, Supplementary Figs. 1-4, 
Supplementary Table 25). Three of four new loci with larger effects in women were 
associated with HIPadjBMI and three of five new loci with larger effects in men were 
associated with WCadjBMI. Most of the 19 loci showed some evidence of association with 
WHRadjBMI in sex-combined or sex-specific analyses, but four loci showed no association 
(P>0.01) with WHRadjBMI, BMI, or height (Supplementary Tables 8, 26).
We next asked whether the genes and pathways influencing these five traits are shared with 
WHRadjBMI or are distinct. Candidate genes were identified based on association with 
other traits, eQTLs, GRAIL, and literature review (Extended Data Table 4, Supplementary 
Tables 8, 11-13, 15-16, 19). Candidate variants identified based on LD (r2>0.7) included 
coding variants in NTAN1 and HMGXB4, and six loci showed significant eQTLs in 
subcutaneous adipose tissue. Based on the literature, several candidate genes are involved in 
adipogenesis and insulin resistance. For example, delayed induction of preadipocyte 
transcription factor ZNF423 in fibroblasts results in delayed adipogenesis38, and NLRP3 is 
part of inflammasome and pro-inflammatory T-cell populations in adipose tissue that 
contribute to inflammation and insulin resistance39. GRAIL analyses identified connections 
that partially overlap with those identified for WHRadjBMI (Supplementary Table 19). 
Taken together, the additional loci appear to function in processes similar to the 
WHRadjBMI loci. The identification of loci that are more strongly associated with 
WCadjBMI or HIPadjBMI than the other anthropometric traits suggests that the additional 
traits characterize aspects of central obesity and fat distribution that are not captured by 
WHRadjBMI or BMI alone.
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DISCUSSION
These meta-analyses of GWAS and Metabochip data in up to 224,459 individuals identified 
additional loci associated with waist and hip circumference measures and help elucidate the 
role of common genetic variation in body fat distribution that is distinct from BMI and 
height. Our results emphasize the strong sexual dimorphism in the genetic regulation of fat 
distribution traits, a characteristic not observed for overall obesity as assessed by BMI36. 
Differences in body fat distribution between the sexes emerge in childhood, become more 
apparent during puberty40, and change with menopause, generally attributed to the influence 
of sex hormones41,42. At loci with stronger effects in one sex than the other, these hormones 
may interact with transcription factors to regulate gene activity.
Annotation of the loci emphasized the role for mesenchymally-derived tissues, especially 
adipose tissue, in fat distribution and central obesity. The development and regulation of 
adipose tissue deposition is closely associated with angiogenesis29, a process highlighted by 
candidate genes at several WHRadjBMI loci. These tissues are implicated in insulin 
resistance, consistent with the enrichment of shared GWAS signals with lipids, T2D, and 
glycemic traits. The identification of skeletal growth processes suggests that the underlying 
genes affect early development and/or differentiation of adipocytes from mesenchymal stem 
cells. In contrast, BMI has a significant neuronal component, involving processes such as 
appetite regulation36. Our results provide a foundation for future biological research in the 
regulation of body fat distribution and its connections with cardiometabolic traits, and offer 
potential target mechanisms for interventions in the risks associated with abdominal fat 
accumulation.
METHODS
Study overview
Our study included 224,459 individuals of European, East Asian, South Asian, and African 
American ancestry. The European ancestry arm included 142,762 individuals from 57 
cohorts genotyped with genome-wide SNP arrays and 67,326 individuals from 44 cohorts 
genotyped with the Metabochip11 (Extended Data Fig. 1, Supplementary Table 1). The non-
European ancestry arm comprised ~1,700 individuals from one cohort of East Asian 
ancestry, ~3,400 individuals from one cohort of South Asian ancestry, and ~9,200 
individuals from six cohorts of African American ancestry, all genotyped with the 
Metabochip. There was no overlap between individuals genotyped with genome-wide SNP 
arrays and Metabochip. For each study, local institutional committees approved study 
protocols and confirmed that informed consent was obtained.
Traits
Our primary trait was WHRadjBMI, the ratio of waist and hip circumferences adjusted for 
age, age2, study-specific covariates if necessary, and BMI. For each cohort, residuals were 
calculated for men and women separately and then transformed by the inverse standard 
normal function. Cohorts with related men and women provided inverse standard normal 
transformed sex-combined residuals. For each cohort, the same transformations were 
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applied to other traits: (i) WHR without adjustment for BMI (WHR); (ii) waist 
circumference with (WCadjBMI) and without (WC) adjustment for BMI; and (iii) hip 
circumference with (HIPadjBMI) and without (HIP) adjustment for BMI.
European ancestry meta-analysis for genome-wide SNP array data
Sample and SNP quality control (QC) were undertaken within each cohort (Supplementary 
Table 3)44. The GWAS scaffold in each cohort was imputed up to CEU haplotypes from 
HapMap resulting in ~2.5 million SNPs. Each directly typed and imputed SNP passing QC 
was tested for association with each trait under an additive model in a linear regression 
framework (Supplementary Table 3). SNP positions are reported based on NCBI Build 36. 
For each cohort, sex-specific association summary statistics were corrected for residual 
population structure using the genomic control inflation factor45 (median λGC=1.01, 
range=0.99 – 1.08). SNPs were removed prior to meta-analysis if they had a minor allele 
count ≤ 3, deviation from Hardy-Weinberg equilibrium exact P<10−6, directly genotyped 
SNP call rate<95%, or low imputation quality (below 0.3 for MACH, 0.4 for IMPUTE, and 
0.8 for PLINK). Association summary statistics for each trait were combined via inverse-
variance weighted fixed-effects meta-analysis and corrected for a second round of genomic 
control to account for structure between cohorts (Extended Data Fig. 1, Supplementary Fig. 
1).
European ancestry meta-analysis for Metabochip data
Sample and SNP QC analyses were undertaken in each cohort (Supplementary Table 3). 
Each SNP passing QC was tested for association with each trait under an additive model 
using linear regression. The Metabochip array11 is enriched, by design, for loci associated 
with anthropometric and cardiometabolic traits, thus, we based our correction on 4,425 
SNPs selected for inclusion based on associations with QT-interval that were not expected to 
be associated with anthropometric traits (>500 kb from variants on Metabochip46 for these 
traits). These study-specific inflation factors had a median λGC=1.01(range 0.93–1.11), with 
only one study exceeding 1.10. After removing SNPs for QC as described in the previous 
section, association summary statistics were combined via inverse-variance weighted fixed-
effects meta-analysis and corrected for a second round of genomic control on the basis of 
QT-interval SNPs to account for structure between cohorts.
European ancestry meta-analyses
Association summary statistics from the two parts of the European ancestry arm were 
combined via inverse-variance weighted fixed-effects meta-analysis using METAL47 with 
no further genomic control correction. Results were reported for SNPs with a sex-combined 
sample size≥50,000. The meta-analyses were repeated for men and women separately for 
each trait. Analyses were corrected for population structure within each sex. The meta-
analysis of WHRadjBMI in men included up to 93,480 individuals, and in women up to 
116,742 individuals.
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Meta-analyses of studies of all ancestries
Sample and SNP QC, tests of association, genomic control correction (median λGC=1.01, 
range=0.90–1.17, with only one study exceeding 1.10), and meta-analyses were performed 
as described above. Association summary statistics from the European and non-European 
ancestry meta-analyses were combined via inverse-variance weighted fixed-effects meta-
analysis without further genomic control correction.
Heterogeneity
For each lead SNP, we tested for sex differences based on the sex-specific beta estimates 
and standard errors, while accounting for potential correlation between estimates as 
previously used in Randall et al10. Similarly, we tested for potential differences in effects 
between European and non-European samples, comparing the effects from GWAS
+Metabochip data for Europeans and Metabochip data for non-Europeans, and we tested for 
differences between population-based studies and samples ascertained on diabetes status, 
and cardiovascular disease, or both. In assessing effects of ascertainment overall, we 
compared effects in seven subsets of our study sample using population-based studies (i.e., 
those not ascertained on any phenotype) as the referent population: 1) all studies ascertained 
on any phenotype, 2) T2D cases, 3) T2D controls, 4) T2D cases+controls, 5) CAD cases, 6) 
CAD controls, and 7) CAD cases+controls. We evaluated significance for heterogeneity 
tests within each comparison using a Bonferroni-corrected p-value of 
0.05/49=0.05/49=1.02×10−3 as well as an FDR threshold48 of <5% (Supplementary Table 
28). Between-study heterogeneity in all meta-analyses was assessed using I2 statistics49.
Heritability and genetic and phenotypic correlations of waist traits
We calculated the heritability and genetic correlations of several central obesity traits using 
variance component models50,51 in the Framingham Heart Study (FHS) and TWINGENE 
study. In this approach, the phenotypic variance is decomposed into additive genetic, non-
additive genetic, and environmental sources of variation (including model error), and for 
sets of traits, the covariances between traits. We report narrow sense heritability (h2), the 
ratio of the additive genetic variance to the total phenotypic variance. Sex-specific inverse 
normal trait residuals, adjusted for age (and cohort in FHS), were used to estimate 
heritability separately in men and women, using variance components analysis in SOLARv.
4.2.752 (FHS) or M×1.70353 (TWINGENE). Additionally, the sex-specific residuals were 
used to conduct bivariate quantitative variance component genetic analyses that calculate 
genetic and environmental correlations between traits. The genetic correlations obtained are 
estimates of the additive effects of shared genes, and a genetic correlation significantly 
different from zero suggests a direct influence of the same genes on more than one trait. 
Similarly, significant environmental correlations suggest shared environmental effects.
We estimated sex-stratified correlations between all waist traits, as well as BMI, height, and 
weight in TWINGENE, FHS, KORA, and EGCUT. In TWINGENE and FHS, age-adjusted 
Pearson correlations were used; in EGCUT and KORA, correlations were adjusted for age 
and age2.
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European ancestry approximate conditional analyses
To evaluate the evidence for multiple association signals within identified loci, we 
performed approximate conditional analyses of sex-combined, women-specific, and men-
specific data as implemented in the GCTA software14,54. This approach makes use of 
association summary statistics from the combined European ancestry meta-analysis and a 
reference dataset of individual-level genotype data to estimate LD between variants and 
hence also the approximate correlation between allelic effect estimates in a joint association 
model.
To evaluate robustness of the GCTA results, we performed analyses using two reference 
datasets: Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) 
consisting of 949 individuals from Uppsala County, Sweden with both GWAS and 
Metabochip genotype data; and Atherosclerosis Risk in Communities (ARIC) consisting of 
6,654 individuals of European descent from four communities in the USA with GWAS data. 
Both GWAS datasets were imputed using data from Phase II of the International HapMap 
Project55. Results shown use the PIVUS reference dataset because Metabochip genotypes 
are available (see a comparison in the Supplementary Note). Assuming that the LD 
correlations between SNPs more than 10 Mb away are zero, and using each reference dataset 
in turn, we performed a genome-wide stepwise selection procedure to select associated 
SNPs one-by-one at a P value<5×10−8. For each locus at which multiple association signals 
were observed in the sex-combined, women-, and/or men-specific data, the SNPs selected 
by GCTA as independently associated with WHRadjBMI in any of the three meta-analyses 
are reported, with the SNP identified in the sex-combined analysis taken by default when 
proxies are identified in the women- and/or men-specific analyses. For SNPs not selected by 
a particular joint conditional analysis, but identified by either of the other two analyses, 
summary statistics were calculated for association analysis of the SNP conditioned on the 
GCTA-selected SNP(s).
Genetic risk score
We calculated a genetic risk score for each individual in the population-based KORA study 
(1,670 men and 1,750 women) using the 49 identified variants, weighted by the allelic effect 
from the European ancestry meta-analyses of WHRadjBMI. Sex-combined scores were 
computed on the basis of the sex-combined meta-analysis. Sex-stratified scores were 
calculated on the basis of men- and women-specific meta-analyses, where SNPs not 
achieving nominal significance in the respective sex (P≥0.05) were excluded. For each 
individual, the sex-combined and sex-stratified risk scores were rounded to the nearest 
integer for plotting. Risk scores were then tested for association with WHRadjBMI using 
linear regression.
Explained variance
We calculated the variance explained by a single SNP as:
Shungin et al. Page 10
Nature. Author manuscript; available in PMC 2015 August 12.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
where MAF is the minor allele frequency, β is the SNP effect estimate computed by meta-
analysis, and Var(Y) is the variance of the phenotype Y as it went into the study-specific 
association testing. To derive the total variance explained by a set of independent SNPs, we 
computed the sum of single-SNP explained variances under the assumption of independent 
contributions.
To estimate the polygenic variance explained by all HapMap SNPs, we used the all-SNP 
estimation approach implemented in GCTA and analysed individuals in the ARIC and 
TwinGene cohorts, including the first 20 principal components as fixed covariates. After 
removing one of each pair of individuals with estimated genetic relatedness>0.025, 11,898 
unrelated individuals with WHRadjBMI were available.
Fine-mapping analyses
We considered each identified locus, defined as 500 kb upstream and downstream of the 
lead SNP, and computed 95% credible intervals using a Bayesian approach. On the basis of 
association summary statistics from the European ancestry, non-European ancestry, or all 
ancestries sex-combined meta-analyses, we calculated an approximate Bayes’ factor56 in 
favor of association, given by:
where βj is the allelic effect of the jth SNP, with corresponding standard error σj, and 
, which incorporates a N(0,0.22) prior for βj. This prior gives high 
probability to small effect sizes, and only small probability to large effect sizes. We then 
calculated the posterior probability that the jth SNP is causal by:
where the summation in the denominator is over all SNPs passing QC across the locus. We 
compared the meta-analysis results and credible sets of SNPs likely to contain the causal 
variant as described57. Assuming a single causal variant at each locus, a 95% credible set of 
variants was then constructed by: (i) ranking all SNPs according to their Bayes’ factor; and 
(ii) combining ranked SNPs until their cumulative posterior probability exceeded 0.95. For 
each locus, we calculated the number of SNPs contained within the 95% credible sets, and 
the length of the genomic interval covered by these SNPs.
Comparison of loci across traits
To determine whether the identified loci were also associated with any of 22 cardio-
metabolic traits, we obtained association data from meta-analysis consortia DIAGRAM 
(T2D)58, CARDIoGRAM-C4D (CAD)59, ICBP (SBP, DBP)60, GIANT (BMI, height)36,37, 
GLGC (HDL, LDL, and TG)61, MAGIC (fasting glucose, fasting insulin, fasting insulin 
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adjusted for BMI, and two-hour glucose)62-64, ADIPOGen (BMI-adjusted adiponectin)65, 
CKDgen (urine albumin-to-creatinine ratio (UACR), estimated glomerular filtration rate 
(eGFR), and overall CKD)66,67, ReproGen (age at menarche, age at menopause)68,69, and 
GEFOS (bone mineral density)70; others provided association data for IgA nephropathy71 
(also Kiryluk K, Choi M, Lifton RP, Gharavi AG, unpublished data) and for endometriosis 
(stage B cases only)72. Proxies (r2>0.80 in CEU) were used when an index SNP was 
unavailable.
We also searched the National Human Genome Research Institute (NHGRI) GWAS Catalog 
for previous SNP-trait associations near our lead SNPs73. We supplemented the catalog with 
additional genome-wide significant SNP-trait associations from the literature13,70,74-80. We 
used PLINK to identify SNPs within 500 kb of lead SNPs using 1000 Genomes Project Pilot 
I genotype data and LD (r2) values from CEU81,82; for rs7759742, HapMap release 22 CEU 
data81,83 were used. All SNPs within the specified regions were compared with the NHGRI 
GWAS Catalog16.
Enrichment of concordant cross-trait associations and effects—To evaluate 
whether the alleles associated with increased WHRadjBMI at the 49 identified SNPs convey 
effects for any of the 22 cardiometabolic traits, we conducted meta-regression analyses of 
the beta-estimates on these metabolic outcomes from other consortia with the beta-estimates 
for WHRadjBMI in our data65.
Based on the association data across traits, we generated a matrix of Z-scores by dividing the 
association betas for each of the 49 WHRadjBMI SNPs for each of 22 traits by their 
respective standard errors. The traits did not include WHRadjBMI or nephropathy in 
Chinese subjects, but did include HIPadjBMI and WCadjBMI. Each Z-score was made 
positive if the original trait-increasing allele also increased the look-up trait and negative if 
not. Missing associations with were assigned a value of zero. We performed unsupervised 
hierarchical clustering of the Z score matrix in R using the default settings of the “heatplot” 
function from the made4 library (version 1.20.0), agglomerating clusters using average 
linkage and Pearson correlation metric distance. The rows and columns of matrix values 
were each automatically scaled to range from 3 to −3. Confidence in the hierarchical 
clustering was assessed by bootstrap analysis (10,000 resamplings) using the R package 
“pvclust”84.
Identification of candidate functional variants—The 1000 Genomes CEU pilot data 
were queried for SNPs within 500 kb and in LD (r2>0.7, an arbitrary threshold) with any 
index SNP. All identified variants were then annotated based on RefSeq transcripts using 
Annovar to identify potential nonsynonymous variants near identified association signals. 
The distance between each variant and the nearest transcription start site were calculated 
using gene annotations from GENCODE (v.12).
To investigate whether SNPs in LD with index SNPs are also in LD with common copy 
number variants (CNVs), we extracted waist trait association results for a list of SNP proxies 
that are in high LD (r2>0.8, CEU) with CNVs in European populations as described 
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previously7. Altogether 6,200 CNV-tagging SNPs were used, which are estimated 
collectively to capture>40% of CNVs>1 kb in size.
Expression quantitative trait loci (eQTLs)—We examined our lead SNPs in eQTL 
datasets from several sources (Supplementary Note) for cis effects significant at P<10−5. 
We then checked if the trait-associated SNP also had the strongest association with the 
expression level of its corresponding transcript. If not, we identified a nearby SNP that had a 
stronger association with expression (peak transcript SNP) of that transcript. To check 
whether effects of the peak transcript SNP and waist trait-associated SNP overlapped, we 
conducted conditional analyses to estimate associations between the waist-associated SNP 
and transcript level when the peak transcript-associated SNP was also included in the model, 
and vice versa. If the association for the expression-associated SNP was not significant 
(P>0.05) when conditioned on the waist-associated SNP, we concluded that the waist-
associated SNP is likely to explain a substantial proportion of the variance in gene transcript 
levels in the region. For SNPs that passed these criteria in either women or men eQTL 
datasets from deCODE, we investigated sex heterogeneity in gene transcript levels for whole 
blood (312 men, 435 women) and subcutaneous adipose tissue (252 men, 351 women) based 
on the sex-specific beta estimates and standard errors, while accounting for potential 
correlation between the sex-specific associations8.
Epigenomic regulatory element overlap with individual variants—We examined 
overlap of regulatory elements with the 68 trait-associated variants and variants in LD with 
them (r2>0.7, 1000 Genomes Phase 1 version 2 EUR85), totaling 1,547 variants. We 
obtained regulatory element data sets from the ENCODE Consortium24 and Roadmap 
Epigenomics Project25 corresponding to eight tissues selected based on a current 
understanding of WHRadjBMI pathways. The 226 regulatory element datasets included 
experimentally identified regions of open chromatin (DNase-seq, FAIRE-seq), histone 
modification (H3K4me1, H3K27ac, H3K4me3, H3K9ac, and H3K4me2), and transcription 
factor binding (Supplementary Table 17). When available, we downloaded data processed 
during the ENCODE Integrative Analysis24. We processed Roadmap Epigenomics 
sequencing data with multiple biological replicates using MACS286 and the same 
Irreproducible Discovery Rate pipeline used in the ENCODE Integrative Analysis. Roadmap 
Epigenomics data with only a single replicate was processed using MACS2 alone.
Global enrichment of WHRadjBMI-associated loci in epigenomic datasets—We 
performed permutation-based tests in a subset of 60 open chromatin (DNase-seq) and 
histone modification (H3K27ac, H3K4me1, H3K4me3, H3K9ac) datasets to identify global 
enrichment of the WHRadjBMI-associated loci. We matched the index SNP at each locus 
with 500 variants having no evidence of association (P>0.5, ~1.2 million total variants) with 
a similar distance to the nearest gene (±11,655 bp), number of variants in LD (±8 variants), 
and minor allele frequency. Using these pools, we created 10,000 sets of control variants for 
each of the 49 loci and identified variants in LD (r2>0.7) and within 1 Mb. For each SNP 
set, we calculated the number of loci with at least one variant located in a regulatory region 
under the assumption that one regulatory variant is responsible for each association signal. 
We initially calculated an enrichment P value by finding the proportion of control sets for 
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which as many or more loci overlap a regulatory element than the set of associated loci. For 
increased P value accuracy, we estimated the P value assuming a sum of binomial 
distributions to represent the number of index SNPs or their LD proxies that overlap a 
regulatory dataset compared to the 500 matched control sets.
GRAIL—Gene Relationships Among Implicated Loci (GRAIL)19 is a text-mining 
algorithm that evaluates the degree of relatedness among genes within trait regions. Using 
PubMed abstracts, a subset of genes enriched for relatedness and a set of keywords that 
suggest putative pathways are identified. To avoid potential bias from papers investigating 
candidate genes stimulated by GWAS, we restricted our search to abstracts published prior 
to 2006. We tested for enrichment of connectivity in the independent SNPs that were 
significant in our study at P<10−5.
MAGENTA—To investigate if pathways including predefined sets of genes were enriched 
in the lower part of the gene P value distribution for WHRadjBMI, we performed a pathway 
analysis using Magenta 2.420 and SNPs present in both the Metabochip and GWAS meta-
analyses. SNPs were assigned to a gene if within 110 kb upstream or 40 kb downstream of 
the transcript’s boundaries. The most significant SNP P value within this interval was 
adjusted for putative confounders (gene size, number of SNPs in a gene, LD pattern) using 
stepwise linear regression, creating a gene association score. If the same SNP was assigned 
to multiple genes, only the gene with the lowest gene score was kept. The HLA region was 
removed from further analyses due to its high LD structure and gene density. Each gene was 
then assigned pathway terms using Gene Ontology (GO), PANTHER, Ingenuity and Kyoto 
Encyclopedia of Genes and Genomes (KEGG)87-90. Finally, the genes were ranked based on 
their gene association score, and a modified gene-set enrichment analysis (GSEA) using 
MAGENTA was performed. This analysis tested for enrichment of gene association score 
ranks above a given rank cutoff (including 5% of all genes) in a gene-set belonging to a 
predefined pathway term, compared to multiple, equally sized gene-sets that were randomly 
sampled from all genes in the genome. 10,000-1,000,000 gene-set permutations were 
performed.
Data-driven Expression-Prioritized Integration for Complex Traits (DEPICT)—
This method is described in detail elsewhere23,36. Briefly, DEPICT uses gene expression 
data derived from a panel of 77,840 expression arrays91, 5,984 molecular pathways (based 
on 169,810 high-confidence experimentally-derived protein-protein interactions92), 2,473 
phenotypic gene sets (based on 211,882 gene-phenotype pairs from the Mouse Genetics 
Initiative93), 737 Reactome pathways94, 184 KEGG pathways95, and 5,083 GO terms19. 
DEPICT uses the expression data to reconstitute the protein-protein interaction gene sets, 
mouse phenotype gene sets, Reactome pathway gene sets, KEGG pathway gene sets, and 
GO term gene sets. To avoid biasing the identification of genes and pathways covered by 
SNPs on the Metabochip, analyses were restricted to GWAS cohort data and included 226 
WHRadjBMI SNPs in 78 non-overlapping loci with sex-combined P<10−5. We used 
DEPICT to map genes to associated WHRadjBMI loci, which then allowed us to (1) 
systematically identify the most likely causal gene(s) in a given associated region, (2) 
identify reconstituted gene sets that were enriched in genes from associated regions, and (3) 
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identify tissue and cell type annotations in which genes from associated regions were highly 
expressed. Associated regions were defined by all genes residing within LD (r2>0.5) 
distance of the WHRadjBMI-associated index SNPs. Overlapping regions were merged, and 
SNPs that mapped near to or within the HLA region were excluded. The 93 WHRadjBMI 
SNPs with P<10−5 (clumping thresholds: HapMap release 27 CEU r2=0.01, 500 kb) resulted 
in 78 non-overlapping regions. GWAS+Metabochip index SNPs were annotated with 
DEPICT-prioritized genes if the DEPICT (GWAS-only) SNP was located within 500 kb. To 
mark related gene sets, we first quantified significant gene sets’ pairwise overlap using a 
non-probabilistic version of the reconstituted gene sets and the Jaccard index measure. 
Groups of gene sets with mutual Jaccard indices >0.25 were subsequently referred to as 
meta gene sets and named by the most significant gene set in the group (Supplementary 
Table 18 and Fig. 2a). In Figures 2a-b, gene sets with similarities between 0.1-0.25 were 
connected by an edge that was scaled according to degree of similarity. The Cytoscape tool 
was used to construct parts of Figure 296. In Figure 2c, we show the significance of all cell 
type annotations and annotations that were categorized as “Tissues” at the outermost level of 
the Medical Subject Heading ontology.
Extended Data
Extended Data Figure 1. Overall WHRadjBMI meta-analysis study design
Data (dashed lines) and analyses (solid lines) related to the genome-wide association study 
(GWAS) cohorts for waist-hip ratio adjusted for body mass index (WHRadjBMI) are 
colored red and those related to the Metabochip (MC) cohorts are colored blue. The two 
genomic control (λGC) corrections (within-study and among-studies) performed on 
associations from each dataset are represented by gray-outlined circles. The λGC corrections 
for the GWAS meta-analysis were based on all SNPs and the λGC corrections for the 
Metabochip meta-analysis were based on a null set of 4,319 SNPs previously associated 
Shungin et al. Page 15
Nature. Author manuscript; available in PMC 2015 August 12.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
with QT interval. The joint meta-analysis of the GWAS and MC datasets is colored purple. 
All SNP counts reflect a sample size filter of N ≥ 50,000 subjects. Additional WHRadjBMI 
meta-analyses included Metabochip data from up to 14,371 subjects of East Asian, South 
Asian, or African American ancestry from eight cohorts. Counts for the meta-analyses of 
waist circumference (WC), hip circumference (HIP), and their BMI-adjusted counterparts 
(WCadjBMI and HIPadjBMI) differ from those of WHRadjBMI because some cohorts only 
had phenotype data available for one type of body circumference measurement (see 
Supplementary Table 2).
Extended Data Figure 2. Female- and male-specific effects, phenotypic variances, and genetic 
correlations
a, Figure showing effect beta estimates for the 20 WHRadjBMI SNPs showing significant 
evidence of sexual dimorphism. Sex-specific effect betas and 95% confidence intervals for 
SNPs associated with waist-hip ratio adjusted for body mass index (WHRadjBMI) are 
shown as red circles and blue squares for women and men, respectively. The SNPs are 
classified into three categories: (i) those showing a female-specific effect (“Women SSE”), 
namely a significant effect in women and no effect in men (Pwomen < 5 × 10−8, Pmen ≥ 
0.05), (ii) those showing a pronounced female effect (“Women CED”), namely a significant 
effect in women and a less significant but directionally consistent effect in men (Pwomen < 5 
× 10−8, 5 × 10−8 < Pmen ≤ 0.05); and (iii) those showing a male-specific effect (“Men 
SSE”), namely a significant effect in men and no effect in women (Pmen < 5 × 10−8, Pwomen 
≥ 0.05). Within each of the three categories, the loci were sorted by increasing P value of 
sex-based heterogeneity in the effect betas. b, Figure showing standardized sex-specific 
phenotypic variance components for six waist-related traits. Values are shown in men (M) 
and women (W) from the Swedish Twin Registry (N = 11,875). The ACE models are 
decomposed into additive genetic components (A) shown in black, common environmental 
components (C) in gray, and non-shared environmental components (E) in white. 
Components are shown for waist circumference (WC), hip circumference (HIP), waist-hip 
ratio (WHR), and their body mass index (BMI)-adjusted counterparts (WCadjBMI, 
HIPadjBMI, and WHRadjBMI). When the A component is different in men and women 
with P < 0.05 for a given trait, its name is marked with an asterisk. c, Table showing genetic 
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correlations of waist-related traits with height, adjusted for age and body mass index. 
Genetic correlations of three traits with height were based on variance component models in 
the Framingham Heart Study and TWINGENE study (see Online Methods). WCadjBMI, 
waist circumference adjusted for BMI; WHRadjBMI, waist-hip ratio adjusted for BMI; 
HIPadjBMI, hip circumference adjusted for BMI.
Extended Data Figure 3. Cumulative genetic risk scores for WHRadjBMI applied to the KORA 
study cohort
a, All subjects (N = 3,440, Ptrend = 6.7 × 10−4). b, Only women (N = 1,750, Ptrend = 1.0 × 
10−11). c, Only men (N = 1,690, Ptrend = 0.02). Each genetic risk score (GRS) illustrates the 
joint effect of the waist-hip ratio adjusted for body mass index (WHRadjBMI)-increasing 
alleles of the 49 identified variants from Table 1 weighted by the relative effect sizes from 
the applicable sex-combined or sex-specific meta-analysis. The mean WHRadjBMI residual 
and 95% confidence interval is plotted for each GRS category (red dots). The histograms 
show each GRS is normally distributed in KORA (gray bars).
Shungin et al. Page 17
Nature. Author manuscript; available in PMC 2015 August 12.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Extended Data Figure 4. Heat map of unsupervised hierarchical clustering of the effects of 49 
WHRadjBMI SNPs on 22 anthropometric and metabolic traits and diseases
The matrix of Z-scores representing the set of associations was scaled by row (locus name) 
and by column (trait) to range from −3 to 3. Negative values (blue) indicate that the waist-
hip ratio adjusted for body mass index (WHRadjBMI)-increasing allele was associated with 
decreased values of the trait and positive values (red) indicate that this allele was associated 
with increased values of the trait. Dendrograms indicating the clustering relationships are 
shown to the left and above the heat map. The WHRadjBMI-increasing alleles at the 49 lead 
SNPs segregate into three major clusters comprised of alleles that associate with: 1) larger 
waist circumference adjusted for BMI (WCadjBMI) and smaller hip circumference adjusted 
for BMI (HIPadjBMI) (n = 30 SNPs); 2) taller stature and larger WCadjBMI (n = 8 SNPs); 
and 3) shorter stature and smaller HIPadjBMI (n = 11 SNPs). The three visually identified 
SNP clusters could be statistically distinguished with >90% confidence. Alleles of the first 
cluster were predominantly associated with lower high density lipoprotein (HDL) 
cholesterol and with higher triglycerides and fasting insulin adjusted for BMI (FIadjBMI). 
eGFRcrea, estimated glomerular filtration rate based on creatinine; LDL cholesterol, low-
density lipoprotein cholesterol; UACR, urine albumin-to-creatinine ratio; BMD, bone 
mineral density.
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Extended Data Figure 5. Regulatory element overlap with WHRadjBMI-associated loci
a, Five variants associated with waist-hip ratio adjusted for body mass index (WHRadjBMI) 
and located ~77 kb upstream of the first CALCRL transcription start site overlap regions 
with genomic evidence of regulatory activity in endothelial cells. b, Five WHRadjBMI 
variants, including rs8817452, in a 1.1 kb region (box) ~250 kb downstream of the first 
LEKR1 transcription start site overlap evidence of active enhancer activity in adipose nuclei. 
Signal enrichment tracks are from the ENCODE Integrative Analysis and the Roadmap 
Epigenomics track hubs on the UCSC Genome Browser. Transcripts are from the 
GENCODE basic annotation.
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Extended Data Table 2
Enrichments of 49 WHRadjBMI signal SNPs with 
metabolic and anthropometric traits
The 49 waist-hip ratio adjusted for body mass index (WHRadjBMI) SNPs were tested for 
association with other traits by GWAS meta-analyses performed by other groups (see Online 
Methods). The maximum sample size available is shown overall or separately for 61 cases/
controls. N indicates the number of the total SNPs for which the WHRadjBMI-increasing 
allele is associated with the trait in the concordant direction (increased levels, except for 
HDL-C, adiponectin, and BMI). One-sided binomial P values test whether this number is 
greater than expected by chance (null P = 0.5 and null P = 0.025, respectively). The tests do 
not account for correlation between WHRadjBMI and the tested traits. P values representing 
significant column-wise enrichment (P < 0.05 / 23 tests) are marked in red and bold.
SNPs in concordant 
direction
SNPs in concordant direction 
with P < 0.05
Trait Max. sample size N Total P N Total P
Type 2 diabetes (T2D) 86,200 37 49 2.35E-04 16 49 3.56E-14
Fasting glucose (FG) 132,996 35 49 1.90E-03 8 49 2.75E-05
Fasting insulin adjusted for 
BMI (FladjBMI) 103,496 45 49 4.11E-10 36 49 4.04E-47
2-hour glucose (G120) 42,853 33 49 1.06E-02 7 49 2.09E-04
Diastolic blood pressure 
(DBP) 69,760 34 49 4.70E-03 10 49 3.21 E-07
Systolic blood pressure 
(SBP) 69,774 38 49 7.10E-05 6 49 1.36E-03
Body mass index (BMI) 322,120 40 49 4.63E-06 23 49 4.42E-24
Height 253,209 25 49 5.00E-01 14 49 1.10E-11
High-density lipoprotein 
cholesterol (HDL-C) 187,142 45 49 4.11E-10 24 49 1.22E-25
Low-density lipoprotein 
cholesterol (LDL-C) 173,067 33 49 1.06E-02 12 49 2.32E-09
Triglycerides (TG) 177,838 46 49 3.49E-11 29 49 6.02E-34
Adiponectin 29,347 41 49 9.82E-07 20 49 1.28E-19
Endometriosis 1,364/7,060 24 45 3.83E-01 4 45 2.58E-02
Nephropathy (in Chinese 
subjects) 1,194/902 18 43 8.89E-01 0 43 1.00E+00
Nephropathy (in Italian 
subjects) 1,045/1,340 20 43 7.29E-01 1 43 6.63E-01
Estimated glomerular 
filtration rate of creatinine 
(eGFRcrea) 74,354 29 49 1.26E-01 3 49 1.24E-01
Chronic kidney disease 
(CKD) 74,354 17 49 9.89E-01 2 49 3.47E-01
Urine albumin-to-creatinine 
ratio (UACR) 31,580 22 49 8.04E-01 2 49 3.47E-01
Menopause 87,802 28 49 1.96E-01 1 49 7.11E-01
Menarche 38,968 23 49 7.16E-01 2 49 3.47E-01
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SNPs in concordant 
direction
SNPs in concordant direction 
with P < 0.05
Trait Max. sample size N Total P N Total P
Coronary artery disease 
(CAD) 191,198 27 48 2.35E-01 9 48 2.64E-06
Femoral neck bone mineral 
density (FN-BMD) 32,960 25 49 5.00E-01 4 49 3.40E-02
Lumbar spine bone mineral 
density (LS-BMD) 31,798 28 49 1.96E-01 3 49 1.24E-01
Extended Data Table 3
Enrichment of 49 WHRadjBMI-associated loci in 
epigenomic datasets
Enrichment of waist-hip ratio adjusted for BMI (WHRadjBMI)-associated loci in regulatory 
elements from selected WHRadjBMI-relevant tissues. P values are derived using a sum of 
binomial distributions (see Methods). P values below a Bonferroni-corrected threshold for 
60 tests of 8.3 × 10−4 are indicated in bold font. The binomial based P values are similar to 
P values generated from 10,000 permutation tests. Dashes indicate that datasets were not 
available.
Sample Tissue DNase I HS H3K4me1 H3K27ac H3K4me3 H3K9ac
Adipose Nuclei Adipose - 9.6E-06 1.2E-13 0.0051 0.0010
GM12878 Blood 0.029 0.032 0.32 0.050 0.030
Osteoblasts Bone 0.082 4.1E-06 1.8E-04 9.9E-04 -
Astrocytes Brain 0.013 0.0044 0.0077 0.0047 -
Anterior Caudate Brain - 2.9E-04 0.026 0.018 0.015
Mid Frontal Lobe Brain - 0.029 0.023 0.023 0.036
Substantia Nigra Brain - 0.047 - 0.023 0.045
Cerebellum Brain 0.048 - - - -
Cerebrum Frontal Brain 0.054 - - - -
Frontal Cortex Brain 0.022 - - - -
HUVEC Endothelial 5.0E-05 0.011 0.0011 0.023 0.040
Adult Liver Liver - 0.0057 - 0.15 0.29
HepG2 Liver 0.015 7.7E-05 0.023 5.0E-04 0.085
Hepatocytes Liver 0.59 - - - -
Huh-7 Liver 0.0024 - - - -
Myoctye Muscle 2.9E-04 1.3E-04 0.0026 0.015 0.0041
PSOAS Muscle 0.0012 - - - -
Skeletal Muscle Muscle - 7.3E-04 7.8E-05 0.0075 0.25
Pancreatic Islet Pancreatic Islets 0.40 0.68 - 0.37 0.61
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Extended Data Table 4
Candidate genes at new loci associated with additional 
waist and hip-related traits
Candidate genes for loci shown on Table 3 based on secondary analyses or literature review. 
Further details are provided in other Supplementary Tables and the Supplementary Note. 
Loci are shown in order of chromosome and position.
SNP Trait Chr Locus
Expression 
QTL (P < 
10−5)*
GRAIL 
(P < 
0.05)† Literature‡ Other GWAS signals§
nsSNPs and CNVs
(r2> 0.7)∥
rs10925060 WCadjBMI 1 OR2W5-NRLP3 - - NLRP3 - -
rs10929925 HIP 2 SOX11 - SOX11 SOX11 - -
rs2124969 WCadjBMI 2 ITGB6 PLA2R1 (SAT) ITGB6 - Idiopathic membranous 
nephropathy (PLA2R1, 
LY75, ITGB6: RBMS1)
-
rs1664789 WCadjBMI 5 ARL15 - - ARL15 - -
rs 17472426 WCadjBMI 5 CCNJL - - FABP6 - -
rs722585 HIPadjBMI 6 GMDS - - - - -
rs7739232 HIPadjBMI 6 KLHL31 KLHL31 (SAT) - KLHL31-GCLC-ELVOL - -
rs1144 WCadjBMI 7 SRPK2 SRPK2 (LCL), 
MLL5 
(Omental)
- - - -
rs13241538 HIPadjBMI 7 KLF14 KLF14 (SAT) - KLF14 HDL cholesterol, 
Triglycerides, Type 2 
diabetes: KLF14
-
rs2398893 WHR 9 PTPDC1 - BARX1 - - -
rs7044106 HIPadjBMI 9 C5 - - - - -
rs11607976 HIP 11 MYEOV - CCND1 FGF19-FGF4-FGF3 - -
rs1784203 WCadjBMI 11 KIAA1731 - - - - -
rs1394461 WHR 11 CNTN5 - - - - -
rs319564 WHR 13 GPC6 - - GPC6 - -
rs4985155 HIP 16 PDXDC1 PDXDC1 (SAT) - PLA2G10-NTAN1 Femoral neck bone 
mineral density, 
Lumbar spine bone 
mineral density, Plasma 
phospholipid levels, 
Metabolic traits, 
Height: PDXDC1, 
NTAN1
NTAN1 (S287P), 
NTAN1 (H283N)
rs2047937 WCadjBMI 16 ZNF423 - - ZNF423-CNEP1R1 - -
rs2034088 HIPadjBMI 17 VPS53 VPS53 (Liver, 
SAT), 
FAM101B 
(Omental, SAT)
- - - -
rs1053593 HIPadjBMI 22 HMGXB4 TOM1 (PBMC), 
HMGXB4 
(Blood, SAT)
- HMGXB4 - HMGXB4 (G165V),
CNVR8147.1
*Gene transcript levels associated with SNP genotype (expression QTL) in the indicated tissue(s).
†Genes in pathways identified as enriched by GRAIL analysis.
‡Strongest candidate genes identified based on manual literature review.
§
Traits associated at P < 5 × 10−8 in GWAS lookups or in the GWAS catalog using the index SNP or a proxy in high 
linkage disequilibrium (LD) (r2 > 0.7), and the genes(s) named in those reports.
∥Nonsynonymous variants (nsSNPs) and copy number variants (CNVs) with tag SNPs in high LD with index SNP based 
on a 1000 Genomes CEU reference panel. DEPICT analysis was not performed for loci associated with these traits. Chr, 
Chromosome; WCadjBMI, waist circumference adjusted for body mass index (BMI); HIPadjBMI, hip circumference 
adjusted for BMI; WHR, waist-to-hip ratio.
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Figure 1. Regional SNP association plots illustrating the complex genetic architecture at two 
WHRadjBMI loci
Sex-combined meta-analysis SNP associations in European individuals were plotted with 
−log10 P values (left y-axis) and estimated local recombination rate in blue (right y-axis). 
Three index SNPs near HOXC6-HOXC13 (a–c) and four near TBX15-WARS2-SPAG17 (d–
g) were identified through approximate conditional analyses of sex-combined or sex-specific 
associations (values shown as Pconditional <5×10−8, see Methods). The signals are 
distinguished by both color and shape, and linkage disequilibrium (r2) of nearby SNPs is 
shown by color intensity gradient.
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Figure 2. Gene set enrichment and tissue expression of genes at WHRadjBMI-associated loci 
(GWAS-only P<10−5)
a, Reconstituted gene sets found to be significantly enriched by DEPICT (FDR<5%) are 
represented as nodes, with pairwise overlap denoted by the width of connecting lines and 
empirical enrichment P value indicated by color intensity (darker is more significant). b, 
The ‘Decreased Liver Weight’ meta-node, which consisted of 12 overlapping gene sets, 
including adiponectin signaling and insulin sensitivity. c, Based on expression patterns in 
37,427 human microarray samples, annotations found to be significantly enriched by 
DEPICT are shown, grouped by type and significance.
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Table 1
WHRadjBMI loci achieving genome-wide significance (P<5×10−8) in sex-combined and/or 
sex-specific meta-analyses
Sex-combined Women Men Sex diff.Pb
SNP Chr Locus EAa EAF β P N β P N β P N
Novel loci achieving genome-wide significance in European-ancestry meta-analyses
rs905938 1 DCST2 T 0.74 0.025 7.3E-10 207,867 0.034 4.9E-10 115,536 0.015 1.10E-02 92,461 1.6E-02
rs10919388 1 GORAB C 0.72 0.024 3.2E-09 181,049 0.033 4.8E-10 102,446 0.013 2.98E-02 78,738 9.8E-03
rs1385167 2 MEIS1 G 0.15 0.029 1.9E-09 206,619 0.023 4.0E-04 114,668 0.036 2.32E-07 92,085 1.6E-01
rs1569135 2 CALCRL A 0.53 0.021 5.6E-10 209,906 0.023 6.9E-07 116,642 0.019 1.48E-04 93,398 5.8E-01
rs10804591 3 PLXND1 A 0.79 0.025 6.6E-09 209,921 0.040 6.1E-13 116,667 0.004 5.28E-01 93,387 5.7E-06
rs17451107 3 LEKR1 T 0.61 0.026 1.1E-12 207,795 0.023 1.0E-06 115,735 0.030 1.42E-08 92,194 3.5E-01
rs3805389 4 NMU A 0.28 0.012 1.5E-03 209,218 0.027 4.6E-08 116,226 −0.007 2.09E-01 93,125 1.6E-06
rs9991328 4 FAM13A T 0.49 0.019 4.5E-08 209,925 0.028 3.4E-10 116,652 0.007 1.69E-01 93,407 8.5E-04
rs303084 4 SPATA5-FGF2 A 0.80 0.023 3.9E-08 209,941 0.029 3.4E-07 116,662 0.016 9.91E-03 93,412 1.1E-01
rs9687846 5 MAP3K1 A 0.19 0.024 7.1E-08 208,181 0.041 3.8E-12 115,897 0.000 9.69E-01 92,417 1.3E-06
rs6556301 5 FGFR4 T 0.36 0.022 2.6E-08 178,874 0.018 7.1E-04 101,638 0.029 1.00E-06 77,370 1.4E-01
rs7759742 6 BTNL2 A 0.51 0.023 4.4E-11 208,263 0.024 1.7E-07 115,648 0.023 5.49E-06 92,749 8.6E-01
rs1776897 6 HMGA1 G 0.08 0.030 1.1E-05 177,879 0.052 6.8E-09 100,516 0.003 7.42E-01 77,497 1.8E-04
rs7801581 7 HOXA11 T 0.24 0.027 3.7E-10 195,215 0.025 7.7E-06 108,866 0.029 2.39E-06 86,483 6.9E-01
rs7830933 8 NKX2-6 A 0.77 0.022 7.4E-08 209,766 0.037 1.2E-12 116,567 0.001 8.35E-01 93,333 1.4E-06
rs12679556 8 MSC G 0.25 0.027 2.1E-11 203,826 0.033 2.1E-10 114,369 0.017 4.15E-03 89,591 2.8E-02
rs10991437 9 ABCA1 A 0.11 0.031 1.0E-08 209,941 0.040 2.8E-08 116,644 0.022 6.13E-03 93,430 7.2E-02
rs7917772 10 SFXN2 A 0.62 0.014 5.6E-05 209,642 0.027 5.5E-09 116,514 −0.001 8.57E-01 93,263 2.3E-05
rs11231693 11 MACROD1-VEGFB A 0.06 0.041 4.5E-08 198,072 0.068 2.7E-11 110,164 0.009 4.20E-01 88,043 2.5E-05
rs4765219 12 CCDC92 C 0.67 0.028 1.6E-15 209,807 0.037 1.0E-14 116,592 0.018 5.32E-04 93,350 5.7E-03
rs8042543 15 KLF13 C 0.78 0.026 1.2E-09 208,255 0.023 6.7E-05 115,760 0.030 1.01E-06 92,629 3.6E-01
rs8030605 15 RFX7 A 0.14 0.030 8.8E-09 208,374 0.031 1.0E-05 115,864 0.031 5.91E-05 92,644 9.9E-01
rs1440372 15 SMAD6 C 0.71 0.024 1.1E-10 207,447 0.022 1.1E-05 115,201 0.027 1.39E-06 92,380 5.2E-01
rs2925979 16 CMIP T 0.31 0.018 1.2E-06 207,828 0.032 3.4E-11 115,431 −0.002 7.86E-01 92,531 1.2E-06
rs4646404 17 PEMT G 0.67 0.027 1.4E-11 198,196 0.034 5.3E-11 115,337 0.017 2.45E-03 87,857 2.6E-02
rs8066985 17 KCNJ2 A 0.50 0.018 1.4E-07 209,977 0.026 4.0E-09 116,683 0.007 1.89E-01 93,428 1.8E-03
rs12454712 18 BCL2 T 0.61 0.016 1.0E-04 169,793 0.035 1.1E-09 96,182 −0.007 2.45E-01 73,576 1.6E-07
rs12608504 19 JUND A 0.36 0.022 8.8E-10 209,990 0.017 2.6E-04 116,689 0.028 1.05E-07 93,435 1.2E-01
rs4081724 19 CEBPA G 0.85 0.035 7.4E-12 207,418 0.033 9.2E-07 115,322 0.039 1.41E-07 92,230 5.0E-01
rs979012 20 BMP2 T 0.34 0.027 3.3E-14 209,941 0.026 1.0E-07 116,668 0.028 6.59E-08 93,407 6.7E-01
rs224333 20 GDF5 G 0.62 0.020 2.6E-08 208,025 0.009 7.4E-02 115,803 0.036 9.00E-12 92,356 6.4E-05
rs6090583 20 EYA2 A 0.48 0.022 6.2E-11 209,435 0.029 2.8E-10 116,382 0.015 2.37E-03 93,187 3.2E-02
Novel loci achieving genome-wide significance in all-ancestry meta-analyses
rs1534696 7 SNX10 C 0.43 0.011 1.3E-03 212,501 0.027 2.1E-08 118,187 −0.006 2.64E-01 92,243 2.1E-06
Previously reported loci achieving genome-wide significance in European-ancestry meta-analyses
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Sex-combined Women Men Sex diff.Pb
SNP Chr Locus EAa EAF β P N β P N β P N
rs2645294 1 TBX15-WARS2 T 0.58 0.031 1.7E-19 209,808 0.035 1.5E-14 116,596 0.027 1.46E-07 93,346 2.0E-01
rs714515 1 DNM3-PIGC G 0.43 0.027 4.4E-15 203,401 0.029 1.8E-10 113,939 0.025 8.54E-07 89,596 5.1E-01
rs2820443 1 LYPLAL1 T 0.72 0.035 5.3E-21 209,975 0.062 5.7E-35 116,672 0.002 6.91E-01 93,437 2.6E-17
rs10195252 2 GRB14-COBLL1 T 0.59 0.027 5.9E-15 209,395 0.052 4.7E-30 116,329 −0.003 5.33E-01 93,199 2.4E-17
rs17819328 3 PPARG G 0.43 0.021 2.4E-09 208,809 0.035 4.6E-14 116,072 0.005 3.26E-01 92,871 5.1E-06
rs2276824 3 PBRM1c C 0.43 0.024 3.2E-11 208,901 0.028 3.7E-09 116,128 0.020 1.35E-04 92,907 2.0E-01
rs2371767 3 ADAMTS9 G 0.72 0.036 1.6E-20 194,506 0.056 1.2E-26 108,624 0.012 3.49E-02 86,016 3.6E-09
rs1045241 5 TNFAIP8-HSD17B4 C 0.71 0.019 4.4E-07 209,710 0.035 6.6E-12 116,560 −0.001 9.29E-01 93,284 8.3E-07
rs7705502 5 CPEB4 A 0.33 0.027 4.7E-14 209,827 0.027 1.9E-08 116,609 0.027 2.30E-07 93,352 1.0E+00
rs1294410 6 LY86 C 0.63 0.031 2.0E-18 209,830 0.037 1.6E-15 116,624 0.025 1.37E-06 93,340 6.3E-02
rs1358980 6 VEGFA T 0.47 0.039 3.1E-27 206,862 0.060 3.7E-34 115,047 0.015 4.02E-03 91,949 3.7E-11
rs1936805 6 RSPO3 T 0.51 0.043 3.6E-35 209,859 0.052 3.7E-30 116,602 0.031 3.08E-10 93,392 1.0E-03
rs10245353 7 NFE2L3 A 0.20 0.035 8.4E-16 210,008 0.041 7.9E-13 116,704 0.027 1.43E-05 93,438 7.2E-02
rs10842707 12 ITPR2-SSPN T 0.23 0.032 4.4E-16 210,023 0.041 6.1E-15 116,704 0.022 1.44E-04 93,453 1.1E-02
rs1443512 12 HOXC13 A 0.24 0.028 6.9E-13 209,980 0.040 1.1E-14 116,688 0.013 2.77E-02 93,425 1.6E-04
rs2294239 22 ZNRF3 A 0.59 0.025 7.2E-13 209,454 0.028 6.9E-10 116,414 0.024 2.31E-06 93,173 5.0E-01
P values and β coefficients for the association with WHRadjBMI in the meta-analyses of combined GWAS and Metabochip studies. The smallest P 
value for each SNP is shown in bold.
a
The effect allele is the WHRadjBMI-increasing allele in the sex-combined analysis.
b
Test for sex difference; values significant at the table-wise Bonferroni threshold of 0.05/49=1.02× 10−3 are marked in bold.
c
Locus previously named NISCH-STAB1. Additional analyses that showed no significant evidence of heterogeneity between studies or due to 
ascertainment are provided in Supplementary Tables 27 and 28 (Supplementary Note). Chr, chromosome; EA, effect allele; EAF, effect allele 
frequency.
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Table 2
Candidate genes at new WHRadjBMI loci
SNP Locus Expression QTL (P<10−5)a GRAIL (P<0.05)b DEPICT (FDR<0.05)c Literatured Other GWAS signalse
rs905938 DCST2 ZBTB7B (PB, Blood) - - - -
rs10919388 GORAB - - - - -
rs1385167 MEIS1 - - - MEIS1 -
rs1569135 CALCRL - TFPI - CALCRL -
rs10804591 PLXND1 - - - PLXND1 -
rs17451107 LEKR1 TIPARP (S,O), LEKR1 (S) - - - Birthweight: CCNL1, LEKR1
rs3805389 NMU - - - NMU -
rs9991328 FAM13A FAM13A (S) - FAM13A - FI: FAM13A
rs303084 SPATA5-FGF2 - FGF2 - FGF2, NUDT6, SPRY1 -
rs9687846 MAP3K1 - MAP3K1 - MAP3K1 FI, TG: ANKRD55, MAP3K1
rs6556301 FGFR4 - MXD3 - FGFR4 Height
rs7759742 BTNL2 HLA-DRA (S), KLHL31 (S) - (not analyzed) - -
rs1776897 HMGA1 - - (not analyzed) HMGA1 Height: HMGA1, C6orf106, 
LBH
rs1534696 SNX10 SNX10 (S), CBX3 (S) - - SNX10 -
rs7801581 HOXA11 - HOXA11 HOXA11 HOXA11 -
rs7830933 NKX2-6 STC1 (S) - - NKX2-6, STC1 -
rs12679556 MSC - EYA1 RP11-1102P16.1 MSC, EYA1 -
rs10991437 ABCA1 - - - ABCA1 -
rs7917772 SFXN2 - - - SFXN2 Height
rs11231693 MACROD1-VEGFB - VEGFB MACROD1 MACROD1, VEGFB -
rs4765219 CCDC92 CCDC92 (S, O, L), ZNF664 
(S, O)
FAM101A - - Adiponectin, FI, HDL, TG: 
CCDC92, ZNF664
rs8042543 KLF13 - KLF13 - KLF13 -
rs8030605 RFX7 - - - -
rs1440372 SMAD6 SMAD6 (Blood) SMAD6 SMAD6 SMAD6 Height
rs2925979 CMIP CMIP (S) - - CMIP, PLCG2 Adiponectin, FI, HDL: 
CMIP
rs4646404 PEMT - - PEMT PEMT -
rs8066985 KCNJ2 - - - KCNJ2 -
rs12454712 BCL2 - - - BCL2 -
rs12608504 JUND KIAA1683 (PB, O), JUND 
(LCL)
JUND - JUND -
rs4081724 CEBPA - CEBPA - CEBPA, CEBPG -
rs979012 BMP2 - BMP2 BMP2 BMP2 Height: BMP2
rs224333 GDF5 CEP250 (S, O), UQCC 
(Blood, S, O, L, LCL)
GDF5 GDF5 GDF5 Height: GDF5, UQCC
rs6090583 EYA2 - EYA2 EYA2 EYA2 -
Candidate genes based on secondary analyses or literature review. Details are provided in Supplementary Tables 8-9, 11-13, 15, 19, 21 and the 
Supplementary Note. The only nonsynonymous variant in high LD with an index SNP was GDF5 S276A. No copy number variants were 
identified.
aGene transcript levels associated with the SNP in the indicated tissue(s): PB, peripheral blood mononuclear cells; S, subcutaneous adipose; O, 
omental adipose; L, liver; lcl, lymphoblastoid cell line.
bGenes in pathways identified as enriched by GRAIL analysis
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cSignificant pathway genes derived by DEPICT using GWAS-only results.
d
Most plausible candidate genes based on literature review.
e
Traits associated at P<5 × 10−8 in GWAS or the GWAS catalog using the index SNP or a proxy, and the genes(s) named. FI, fasting insulin 
adjusted for BMI; HDL, high-density lipoprotein cholesterol; tg, triglycerides.
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